Light Activation of Anti-CD3 in vivo Reduces the Growth of an Aggressive Ovarian Carcinoma
- 12 November 2007
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 2 (11) , 1591-1593
- https://doi.org/10.1002/cmdc.200700116
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Light-Directed Activation of Human T-CellsChemMedChem, 2007
- How specific are therapeutic monoclonal antibodies?The Lancet, 2006
- Antibody targeted drugs as cancer therapeuticsNature Reviews Drug Discovery, 2006
- Flash photolysis using a light emitting diode: An efficient, compact, and affordable solutionCell Calcium, 2005
- Retargeting T cells and immune effector cells with bispecific antibodiesPublished by Elsevier ,2005
- Light activatable antibodies: Models for remotely activatable proteinsNature Medicine, 1996
- Studies on photocleavable nitrobenzyl-bovine serum albumin conjugatesBiochemical Society Transactions, 1995
- The modulation of Protein A-IgG(Fc) binding by the reversible addition of 2-nitrobenzyl groupsBiochemical Society Transactions, 1995
- In Vivo Administration of Anti-CD3 Prevents Malignant Progressor Tumor GrowthScience, 1988